Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CCI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, descriptive and observational study of the anticancer center practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| study population | Patient with cancer requiring a long-term central venous catheter |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and collection of complications for the patients requiring an implantable central venous access ports substitution/change | Until the implantable central venous access ports removal |
| Measure | Description | Time Frame |
|---|---|---|
| Brief description of the different risk factor for morbidity | Until the implantable central venous access ports removal | |
| Assessment of the implantable central venous access ports ease-of-use for nurses according to the modalities of implementation and patient features |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All the patients requiring the implementation of a catheter in an anticancerous center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fabrice NARDUCCI, MD | Centre Oscar Lambret | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Oscar Lambret | Lille | 59020 | France |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Until the implantable central venous access ports removal |
| Assessment of the patient quality of life | Before central venous access ports implementation, at the first day of chemotherapy, and during the cycle 4 of chemotherapy |